Recently, the Center for Drug Evaluation (CDE) of the National Medical Products Administration announced that the clinical trial application (IND) for the mRNA vaccine YKKYY025 injection for the prevention of respiratory syncytial virus (RSV) submitted by Hangzhou Tianlong Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Yuekang Pharmaceutical, has been accepted. Prior to this, this vaccine had obtained clinical trial approval from the US FDA earlier this year. Understanding and meeting unmet clinical needs has always been the core direction and critical path of our research and development work, “said Yu Weishi, Chairman of Yuekang Pharmaceutical Group. It is reported that in addition to RSV vaccine, Yuekang Pharmaceutical has obtained overseas clinical approvals for multiple innovative drugs. On January 21st, the clinical trial application for YKY026 injection, an mRNA vaccine independently developed by Yuekang Pharmaceutical for the prevention of herpes zoster, was officially accepted by CDE. Due to its previous clinical ...
Recently, MicroPort Xintong Medical Technology Co., Ltd. (hereinafter referred to as Xintong Medical) announced that its subsidiary Shanghai Zuoxin Medical Technology Co., Ltd. has developed AnchorMan ® The left atrial appendage occlusion system has successfully obtained the EU CE MDR certification, becoming the first left atrial appendage occlusion system in China to receive this certification. In addition, the AnchorMan used in conjunction with it ® The left atrial appendage guidance system was also approved for market by the European Union during the same period. The first and only product in the country In recent years, with the further growth of the aging population, the incidence rate of atrial fibrillation has increased year by year. Among them, thromboembolism is the most common complication of atrial fibrillation, with the highest incidence and greatest harm of stroke. The stroke rate of atrial fibrillation patients is five times higher than that of the general ...
On January 15, 2025, Eli Lilly and Company announced that the FDA has approved Omvoh (mirikizumab mrkz) for the treatment of moderate to severe active Crohn’s disease (CD) in adults. After being approved as the first treatment for moderate to severe active ulcerative colitis (UC) in adults in October 2023, Omvoh has now been approved in the United States for the treatment of two inflammatory bowel diseases (IBD). Mirikizumab mrkz is a humanized IgG4 monoclonal antibody that selectively binds to the p19 subunit of human IL-23 cytokine. By blocking the interaction with IL-23 receptors, mirikizumab inhibits the release of pro-inflammatory cytokines and chemokines. This is the first biologic therapy to provide two-year, three-year efficacy data for Crohn’s disease upon approval. This drug aims to reduce inflammation of the gastrointestinal tract, which is an important aspect of Crohn’s disease pathology. In addition, Eli Lilly has submitted listing applications for Omvoh for ...
On February 25, temperature control is crucial in the field of aviation cold chain transportation, especially in the transportation of vaccines and biopharmaceuticals. CIMC, headquartered in Shenzhen, announced on the 25th that it had successfully developed the first RAP active temperature-controlled aviation box in China. It not only fills the gap in similar products in China, but also enables “heaven-earth linkage” full-process tracking to ensure that medicines do not lose the “cold chain”. For a long time, Chinese airlines have mainly relied on aviation boxes leased from abroad, which is costly. In 2020, Qingdao CIMC Special Refrigeration Equipment Co., Ltd. (hereinafter referred to as “CIMC Qingdao Refrigerated Special Box”), a subsidiary of CIMC, developed the first RKN active temperature-controlled aviation container in China, breaking the foreign monopoly in one fell swoop. The RKN air box is powered by a battery and uses a refrigeration unit to control the temperature inside ...
On February 25, the Hong Kong stock price of CanSino Biologics (06185.HK, share price of HK$37.35, market value of HK$9.2 billion) once soared by more than 15%. On the news front, the company issued an announcement the day before, saying that the adsorbed acellular pertussis (component) Haemophilus influenzae type b (combined)-ACYW135 group meningococcal (combined) combined vaccine (DTcP-Hib-MCV4) has been approved for drug clinical trials. This is a pentavalent vaccine that prevents multiple diseases at the same time. It has three components: the first Asian quadrivalent meningococcal conjugate vaccine “Manhaixin” that has been approved for marketing, the second is the adsorbed acellular diphtheria (component) pertussis combined vaccine for infants and young children in the phase III clinical stage, and the third is the Hib vaccine (Haemophilus influenzae type b vaccine) in the phase I clinical stage. It is worth noting that this is the first domestic pentavalent vaccine to reach the ...
Recently, the National Drug Administration Drug Evaluation Center (CDE) announced that the clinical trial application (IND) for the mRNA vaccine YKYY025 injection for the prevention of respiratory syncytial virus (RSV) submitted by Hangzhou Tianlong Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Yuekang Pharmaceutical, has been accepted. Prior to this, this vaccine had been approved for clinical trials by the US FDA at the beginning of this year. “Insight into and meeting clinical needs that have not yet been fully responded to have always been the core orientation and key path for our research and development work.” Yu Weishi, chairman of Yuekang Pharmaceutical Group, said. It is reported that in addition to RSV vaccines, Yuekang Pharmaceutical has obtained overseas clinical approval for a number of innovative drugs. On January 21, Yuekang Pharmaceutical’s independently developed mRNA vaccine YKYY026 injection for the prevention of herpes zoster was officially accepted by CDE. Since it ...
DeepSeek is penetrating into various industries. In February 2025, the domestic large model DeepSeek-R1 was fully open source and adapted to multiple fields, and AI medical care also entered a new stage of technology integration and industry reconstruction. Many companies including Aimi Vaccine, Hengrui Medicine, and Zhiyun Health announced that they are combining with AI large models such as DeepSeek. Take the recent announcement of Aimi Vaccine as an example. It stated that as a leading vaccine company in China, the group actively responded to the national “AI+” industrial development strategy and fully deployed access to the DeepSeek large model. However, the financial report of Aimi Vaccine shows that it has faced continuous losses in recent years. To what extent can DeepSeek reduce costs and increase efficiency? Many industry analysts consulted by Blue Whale Finance all said that overall, they are optimistic about the application of AI big models such ...
Recently, Shiyao Group announced that its subsidiary Shiyao Jushi has signed an exclusive authorization agreement with Radiance Biopharma for the antibody conjugate drug SYS6005. Since 2025, several pharmaceutical companies, including Xinda Biotechnology and Xiansheng Pharmaceutical, have signed large orders with potential amounts of up to 1 billion US dollars. Industry insiders believe that the overall progress of domestic new drug research and development is commendable, and Chinese pharmaceutical companies with strong research and development capabilities are expected to compete with foreign-funded enterprises in the global market. They are optimistic about the prospects of domestic new drug research and development and going global in 2025. Multiple products achieve overseas authorization According to the announcement from Shiyao Group, Shiyao Giant Stone has agreed to grant Radiance Biopharma exclusive authorization to develop and commercialize SYS6005 in the United States, European Union, United Kingdom, Switzerland, Norway, Iceland, Liechtenstein, Albania, Montenegro, North Macedonia, Serbia, Australia, ...
On February 21, 2025, Boston Scientific (NYSE: BSX) announced that its fully funded subsidiary, American Medical Systems Europe B.V. (“AMS Europe”), has priced a total of 1.5 billion euros (approximately RMB 11.377 billion) in notes (a type of bond issuance). The funds obtained from this issuance, along with the company’s cash on hand, will be used for debt repayment, working capital, and potential future acquisitions. As of February 21st, Boston Scientific’s latest stock price is $104.49 per share, with a total market value of $154 billion, reaching its highest point since going public. 01. Issuing bonds worth billions, PFA’s performance skyrocketed by 172% The notes issued this time consist of two transactions, one with a total principal of 850 million euros and an interest rate of 3.000%, due in 2031; The other principal amount is 650 million euros, with an interest rate of 3.250%, due in 2034. The bill will ...
Recently, the National Medical Products Administration’s Device Review Center released the results of the special review application for innovative medical devices (No. 2 of 2025), intending to approve 9 medical devices to enter the innovation channel. 1. Peripheral arterial stent graft system: Jiangsu Pupeng Medical Technology Co., Ltd Pupeng Medical was established on December 16, 2019, and is a subsidiary of Jiangsu Zhenyi Medical Technology Co., Ltd. (hereinafter referred to as Zhenyi Medical). It is reported that Zhenyi Medical focuses on the cardiovascular disease field with extremely high mortality and disability rates, and the domestic market is still blank. Its business comprehensively covers multiple interventional treatment fields such as heart valves, peripheral and coronary arteries. It is the first platform enterprise to achieve one-stop innovative solutions for blood flow management on a global scale. In addition to the products that entered the innovation channel this time, Park Peng Medical also ...
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.